Cristina Sánchez

Cristina Sánchez

Auto-generated profile, based on publicly available information

Cristina Sánchez

Department of Biochemistry and Molecular Biology, Complutense University, Madrid, Spain

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
IGIsmael Galve-Roperh
Ismael Galve-Roperh
CSCristina Sánchez
Cristina Sánchez
MCMaría Luisa Cortés
María Luisa Cortés
TPTeresa Gómez del Pulgar
Teresa Gómez del Pulgar
MIMarta Izquierdo
Marta Izquierdo
MGManuel Guzmán
Manuel Guzmán

4 May 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
GDGuillermo Velasco Díez
Guillermo Velasco Díez
CSCristina Sánchez
Cristina Sánchez
MGManuel Guzmán
Manuel Guzmán

27 June 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MGManuel Guzmán
Manuel Guzmán
MDM J Duarte
M J Duarte
CBC Blázquez
C Blázquez
JRJ Ravina
J Ravina
MRM C Rosa
M C Rosa
LGL González-Feria
L González-Feria
Δ9-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression. The primary end point of the study was to determine the safety of intracranial THC administration. We also evaluated THC action on the length of survival and various tumour-cell parameters. A dose escalation regimen for THC administration was assessed. Cannabinoid delivery was safe and could be achieved without overt psychoactive effects. Median survival of the cohort from the beginning of cannabinoid administration was 24 weeks (95% confidence interval: 15–33). Δ9-Tetrahydrocannabinol inhibited tumour-cell proliferation in vitro and decreased tumour-cell Ki67 immunostaining when administered to two patients. The fair safety profile of THC, together with its possible antiproliferative action on tumour cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.

1 February 2016 in Current Oncology
Verified
Journal Article
Open access
GDGuillermo Velasco Díez
Guillermo Velasco Díez
CSC. Sánchez
C. Sánchez
MGManuel Guzmán
Manuel Guzmán
In addition to the well-known palliative effects of cannabinoids on some cancer-associated symptoms, a large body of evidence shows that these molecules can decrease tumour growth in animal models of cancer. They do so by modulating key cell signalling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and decrease metastasis in various tumour types in laboratory animals. In this review, we discuss the current understanding of cannabinoids as antitumour agents, focusing on recent discoveries about their molecular mechanisms of action, including resistance mechanisms and opportunities for their use in combination therapy. Those observations have already contributed to the foundation for the development of the first clinical studies that will analyze the safety and potential clinical benefit of cannabinoids as anticancer agents.

25 September 1998 in FEBS Letters
Verified
Journal Article
Closed access
CSCristina Sánchez
Cristina Sánchez
IGIsmael Galve-Roperh
Ismael Galve-Roperh
CCCecile Canova
Cecile Canova
PBPhilippe Brachet
Philippe Brachet
MGManuel Guzmán
Manuel Guzmán

1 July 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
MCMaria Caffarel
Maria Caffarel
DSDavid Sarrió
David Sarrió
JPJosé Palacios
José Palacios
MGManuel Guzmán
Manuel Guzmán
CSCristina SánChez
Cristina SánChez
It has been proposed that cannabinoids are involved in the control of cell fate. Thus, these compounds can modulate proliferation, differentiation, and survival in different manners depending on the cell type and its physiopathologic context. However, little is known about the effect of cannabinoids on the cell cycle, the main process controlling cell fate. Here, we show that Δ9-tetrahydrocannabinol (THC), through activation of CB2 cannabinoid receptors, reduces human breast cancer cell proliferation by blocking the progression of the cell cycle and by inducing apoptosis. In particular, THC arrests cells in G2-M via down-regulation of Cdc2, as suggested by the decreased sensitivity to THC acquired by Cdc2-overexpressing cells. Of interest, the proliferation pattern of normal human mammary epithelial cells was much less affected by THC. We also analyzed by real-time quantitative PCR the expression of CB1 and CB2 cannabinoid receptors in a series of human breast tumor and nontumor samples. We found a correlation between CB2 expression and histologic grade of the tumors. There was also an association between CB2 expression and other markers of prognostic and predictive value, such as estrogen receptor, progesterone receptor, and ERBB2/HER-2 oncogene. Importantly, no significant CB2 expression was detected in nontumor breast tissue. Taken together, these data might set the bases for a cannabinoid therapy for the management of breast cancer.(Cancer Res 2006; 66(13): 6615-21)